1069 / 1224
Example: overview of optimum level of uncertainties
for different clinical sites
(
BRAPHYQS AAPM guidelines 2014, Radiother
Oncol 110)
BT application
HDR
192
Ir gyn
vaginal
HDR
192
Ir ic
cervix
HDR
192
Ir
breast
balloon*
LDR
125
I
prostate
HDR
192
Ir
prostate
Source strength
2% 2% 2% 3% 2%
Treatment planning
3% 3% 3% 4% 3%
Medium dosimetric corrections
1% 1% 3% 5% 1%
Dose delivery including registration
of applicator geometry to anatomy
5% 4% 7% 4%** 2%
Interfraction/Intrafraction changes
5% 11% 7% 7% 2%
…
Total dosimetric uncertainty
(for one fraction)
~8% ~12% ~13% ~11% ~5%
*additional scatter dosimetric corrections (skin, surface): 7%
** inter-seed attenuation
*** additional imaging and planning based uncertainties, see original publication